September 11, 2025Ageing Research ReviewsOpen Access

Use of Factor XI/XIa Inhibitors in Patients with Atrial Fibrillation: Current Progress and Future Prospects

View Full Paper

Ask AI

Bookmark

Novel factor xi/xia inhibitors in atrial fibrillation showed favorable safety profiles with reduced bleeding risks.
Clinical trials have demonstrated some efficacy in preventing thromboembolic events compared to traditional anticoagulants.
The review discusses the rationale for using factor xi/xia inhibitors in elderly patients, emphasizing improved anticoagulation therapy.
Future trials are essential to further evaluate long-term safety and efficacy of these novel agents in atrial fibrillation.

Discussion

No takes yet. Share an insight, caveat, or question.

Narrative review highlights safety and efficacy of novel anticoagulants in elderly atrial fibrillation patients, suggesting improved outcomes.

Fan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Narrative review highlights safety and efficacy of novel anticoagulants in elderly atrial fibrillation patients, suggesting improved outcomes.